Literature DB >> 17018300

MicroRNA pathways modulate polyglutamine-induced neurodegeneration.

Julide Bilen1, Nan Liu, Barrington G Burnett, Randall N Pittman, Nancy M Bonini.   

Abstract

Nine human neurodegenerative diseases are due to expansion of a CAG repeat- encoding glutamine within the open reading frame of the respective genes. Polyglutamine (polyQ) expansion confers dominant toxicity, resulting in neuronal degeneration. MicroRNAs (miRNAs) have been shown to modulate programmed cell death during development. To address whether miRNA pathways play a role in neurodegeneration, we tested whether genes critical for miRNA processing modulated toxicity induced by the spinocerebellar ataxia type 3 (SCA3) protein. These studies revealed a striking enhancement of polyQ toxicity upon reduction of miRNA processing in Drosophila and human cells. In parallel genetic screens, we identified the miRNA bantam (ban) as a potent modulator of both polyQ and tau toxicity in flies. Our studies suggest that ban functions downstream of toxicity of the SCA3 protein, to prevent degeneration. These findings indicate that miRNA pathways dramatically modulate polyQ- and tau-induced neurodegeneration, providing the foundation for new insight into therapeutics.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17018300     DOI: 10.1016/j.molcel.2006.07.030

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  115 in total

1.  Viral delivery of miR-196a ameliorates the SBMA phenotype via the silencing of CELF2.

Authors:  Yu Miyazaki; Hiroaki Adachi; Masahisa Katsuno; Makoto Minamiyama; Yue-Mei Jiang; Zhe Huang; Hideki Doi; Shinjiro Matsumoto; Naohide Kondo; Madoka Iida; Genki Tohnai; Fumiaki Tanaka; Shin-ichi Muramatsu; Gen Sobue
Journal:  Nat Med       Date:  2012-07       Impact factor: 53.440

Review 2.  Modifiers and mechanisms of multi-system polyglutamine neurodegenerative disorders: lessons from fly models.

Authors:  Moushami Mallik; Subhash C Lakhotia
Journal:  J Genet       Date:  2010-12       Impact factor: 1.166

Review 3.  Role of noncoding RNAs in trinucleotide repeat neurodegenerative disorders.

Authors:  Huiping Tan; Zihui Xu; Peng Jin
Journal:  Exp Neurol       Date:  2012-01-27       Impact factor: 5.330

4.  Transcriptional profiling reveals that C5a alters microRNA in brain endothelial cells.

Authors:  Michael T Eadon; Alexander Jacob; Patrick N Cunningham; Richard J Quigg; Joe G N Garcia; Jessy J Alexander
Journal:  Immunology       Date:  2014-11       Impact factor: 7.397

Review 5.  Animal models of polyglutamine diseases and therapeutic approaches.

Authors:  J Lawrence Marsh; Tamas Lukacsovich; Leslie Michels Thompson
Journal:  J Biol Chem       Date:  2008-10-28       Impact factor: 5.157

Review 6.  Short non-coding RNA biology and neurodegenerative disorders: novel disease targets and therapeutics.

Authors:  Marc S Weinberg; Matthew J A Wood
Journal:  Hum Mol Genet       Date:  2009-04-15       Impact factor: 6.150

7.  Conservation of miR-15a/16-1 and miR-15b/16-2 clusters.

Authors:  Junming Yue; Gabor Tigyi
Journal:  Mamm Genome       Date:  2009-12-16       Impact factor: 2.957

Review 8.  Pharmacology of epigenetics in brain disorders.

Authors:  Pritika Narayan; Mike Dragunow
Journal:  Br J Pharmacol       Date:  2009-12-15       Impact factor: 8.739

9.  Huntington's disease protein contributes to RNA-mediated gene silencing through association with Argonaute and P bodies.

Authors:  Jeffrey N Savas; Anthony Makusky; Søren Ottosen; David Baillat; Florian Then; Dimitri Krainc; Ramin Shiekhattar; Sanford P Markey; Naoko Tanese
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-31       Impact factor: 11.205

Review 10.  Understanding microRNAs in neurodegeneration.

Authors:  Stephen M Eacker; Ted M Dawson; Valina L Dawson
Journal:  Nat Rev Neurosci       Date:  2009-11-11       Impact factor: 34.870

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.